Whether AC Immune represents a sound addition to your portfolio depends entirely on your risk tolerance, investment horizon, and interest in the biotechnology sector. The company's pioneering work in precision medicine for neurodegenerative diseases, backed by substantial partnership grants and milestone agreements, offers unique long-term potential. However, the absence of commercialized product sales means the company relies heavily on ongoing research milestones and capital management. Thoroughly reviewing clinical trial pipelines, financial burn rates, and professional analyst research is strongly advised before executing any investment trades.